GlaxoSmithKline has announced a new partnership with Exscientia that will harness the power of artificial intelligence (AI) to discover new drug targets.
The strategic drug discovery collaboration will see Exscientia apply its AI-enabled platform to identify novel and selective small molecules for up to ten disease-related targets selected by GlaxoSmithKline that span multiple therapeutic areas.
“GlaxoSmithKline has formed a new strategic collaboration with AI-driven drug discovery company Exscientia.“
GlaxoSmithKline will contribute its own drug discovery expertise to aid this work, with Exscientia to receive research payments and milestone fees that could reach a total of 33 million pounds if all objectives are achieved.
Exscientia has been specifically incentivised to reduce the number of compounds required for synthesis and assay in order to achieve lead and candidate compound goals, utilising Big Data techniques and AI-driven algorithms.
John Baldoni, senior vice-president for platform science and technology at GlaxoSmithKline, said: "Exscientia has built an excellent team with proven innovation in drug discovery technologies. We anticipate that their industry-leading approach will accelerate the discovery of new molecules against high-value GlaxoSmithKline targets."
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.See all the latest jobs in Pharmaceutical